4D Molecular Therapeutics Completes Enrollment for 4FRONT-1 Clinical Trial
4D Molecular Therapeutics announced enrollment completion for 4FRONT-1, the first Phase 3 clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration. 4FRONT-1 is a Phase 3 multicenter, randomized, double-masked, aflibercept 2 mg comparator-controlled study of intravitreal 4D-150 in wet AMD. The primary endpoint is non-inferiority in the mean change from baseline in best corrected visual acuity at 52 weeks. The key secondary endpoint is treatment burden reduction comparing the number of aflibercept injections received in the 4D-150 arm versus the aflibercept comparator arm over 52 weeks. Patients in both arms will be eligible for supplemental aflibercept injections. 4FRONT-1 is evaluating treatment-naive wet AMD patients at sites in North America. Topline primary endpoint data from 4FRONT-1 is expected in H1 2027. The second Phase 3 for wet AMD, 4FRONT-2, is a global trial with an identical design to 4FRONT-1 except for enrolling both treatment-naive and recently diagnosed treatment-experienced wet AMD patients. 4FRONT-2 is expected to complete enrollment in H2 2026 with topline primary endpoint data expected in H2 2027.
Trade with 70% Backtested Accuracy
Analyst Views on FDMT
About FDMT
About the author
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees
- Employee Incentive Program: On January 13, 2026, 4D Molecular Therapeutics' compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees, aimed at attracting talent and enhancing team stability.
- Equity Grant Context: The RSUs were awarded under the 2025 Employment Inducement Award Plan, approved by the board in February 2025, complying with Nasdaq Rule 5635(c)(4), reflecting the company's commitment to talent acquisition.
- Product Development Progress: The company's lead product, 4D-150, is currently in Phase 3 trials, designed to provide multi-year sustained delivery of anti-VEGF through a single safe intravitreal injection, significantly reducing the treatment burden associated with current methods, showcasing transformative potential.
- Gene Therapy Innovation: The second candidate, 4D-710, is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients, demonstrating the company's innovative capabilities and market potential in the therapeutic landscape.
Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are mostly higher, with Nasdaq 100 futures gaining around 100 points on Friday.
BlackBerry Earnings Report: BlackBerry Ltd reported third-quarter revenue of $141.8 million, exceeding analyst expectations, but shares fell 4.6% in pre-market trading.
Other Stocks Declining: Several stocks, including Aimei Health Technology and Nike Inc, experienced significant declines in pre-market trading despite some reporting better-than-expected earnings.
Market Overview: The overall market sentiment is cautious, with various stocks showing downward trends following recent earnings reports and inflation data.
4D Molecular Shares Decline Following Initial Trial Results for Cystic Fibrosis Treatment
Stock Performance: 4D Molecular Therapeutics (FDMT) shares fell approximately 15% following the announcement of updated data from an early-stage trial for its cystic fibrosis therapy, 4D-710.
Trial Findings: The Phase 1 AEROW clinical trial indicated no new safety events in higher-dose groups, leading the company to select a specific dose for the upcoming Phase 2 trial.
Trial Design: The AEROW trial evaluated different doses of 4D-710 in adults with cystic fibrosis lung disease who cannot tolerate standard CFTR modulator therapy.
Future Plans: 4D Molecular Therapeutics aims to complete enrollment for the Phase 2 Dose-Expansion cohort by the first half of 2026, with a program update anticipated in the latter half of the year.
4D Molecular Therapeutics Reports Positive Interim Data for 4D-710 in Cystic Fibrosis Trial
- Positive Clinical Data: 4D-710 demonstrated good tolerability and achieved physiologically relevant CFTR expression levels in the AEROW trial, indicating potential clinical benefits across multiple lung function and symptom measures, suggesting its promise as a cystic fibrosis treatment.
- Patient Recruitment Progress: As of December 1, 2025, the AEROW trial has enrolled 16 cystic fibrosis patients, with no new safety events reported across different dose cohorts, underscoring the treatment's safety and efficacy.
- Successful Dose Selection: The 2.5E14 vg dose cohort showed clinically meaningful activity across all endpoints, supporting its selection for the next phase and further optimizing the treatment regimen.
- Future Milestones: The company anticipates completing enrollment of the AEROW Phase 2 Dose-Expansion cohort in H1 2026, further validating the efficacy of 4D-710, with plans to share additional updates in H2 2026.
4D Molecular Therapeutics Announces Encouraging Interim Phase 1 Results for 4D-710 in Cystic Fibrosis
Positive Interim Results: 4D Molecular Therapeutics reported encouraging interim results from its Phase 1 AEROW study for 4D-710, a gene therapy for cystic fibrosis, showing significant improvements in lung function over a one-year follow-up.
Durable CFTR Expression: The study demonstrated sustained CFTR transgene expression within the therapeutic range for at least one year, indicating potential long-term benefits for patients.
Future Plans: The company anticipates completing enrollment for the Phase 2 dose-expansion cohort by mid-2026, with an update on the program expected in the latter half of 2026.
Stock Performance: Following the announcement, FDMT shares rose by 5.21%, closing at $11.52.
4D Molecular Therapeutics Grants 13,800 RSUs to New Employees Under Inducement Plan
- Employee Incentive Program: On December 9, 2025, 4D Molecular Therapeutics granted 13,800 Restricted Stock Units (RSUs) to three new non-executive employees, aimed at attracting new talent through the 2025 Employment Inducement Award Plan, thereby enhancing the company's human resource competitiveness.
- Board Approval: The plan was approved by the board in February 2025, complying with Nasdaq Global Market Rule 5635(c)(4), indicating the company's commitment to attracting and retaining key talent, which will further drive its biotechnology innovations.
- Product Development Context: The company's lead product candidate, 4D-150, is currently in Phase 3 clinical trials, designed to provide multi-year sustained anti-VEGF delivery through a single safe intravitreal injection, significantly reducing the treatment burden associated with current methods and improving patient experience.
- Market Potential: With the development of product candidates like 4D-150 and 4D-710, the company is poised to achieve breakthroughs in treating blinding retinal vascular diseases and cystic fibrosis, further solidifying its market position in the biotechnology sector.
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees
- Employee Incentive Program: On January 13, 2026, 4D Molecular Therapeutics' compensation committee granted 23,600 Restricted Stock Units (RSUs) to four new non-executive employees, aimed at attracting talent and enhancing team stability.
- Equity Grant Context: The RSUs were awarded under the 2025 Employment Inducement Award Plan, approved by the board in February 2025, complying with Nasdaq Rule 5635(c)(4), reflecting the company's commitment to talent acquisition.
- Product Development Progress: The company's lead product, 4D-150, is currently in Phase 3 trials, designed to provide multi-year sustained delivery of anti-VEGF through a single safe intravitreal injection, significantly reducing the treatment burden associated with current methods, showcasing transformative potential.
- Gene Therapy Innovation: The second candidate, 4D-710, is the first known genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients, demonstrating the company's innovative capabilities and market potential in the therapeutic landscape.
Major Stocks Including BlackBerry, FedEx, and Nike Decline in Friday's Pre-Market Trading
U.S. Stock Futures: U.S. stock futures are mostly higher, with Nasdaq 100 futures gaining around 100 points on Friday.
BlackBerry Earnings Report: BlackBerry Ltd reported third-quarter revenue of $141.8 million, exceeding analyst expectations, but shares fell 4.6% in pre-market trading.
Other Stocks Declining: Several stocks, including Aimei Health Technology and Nike Inc, experienced significant declines in pre-market trading despite some reporting better-than-expected earnings.
Market Overview: The overall market sentiment is cautious, with various stocks showing downward trends following recent earnings reports and inflation data.
4D Molecular Shares Decline Following Initial Trial Results for Cystic Fibrosis Treatment
Stock Performance: 4D Molecular Therapeutics (FDMT) shares fell approximately 15% following the announcement of updated data from an early-stage trial for its cystic fibrosis therapy, 4D-710.
Trial Findings: The Phase 1 AEROW clinical trial indicated no new safety events in higher-dose groups, leading the company to select a specific dose for the upcoming Phase 2 trial.
Trial Design: The AEROW trial evaluated different doses of 4D-710 in adults with cystic fibrosis lung disease who cannot tolerate standard CFTR modulator therapy.
Future Plans: 4D Molecular Therapeutics aims to complete enrollment for the Phase 2 Dose-Expansion cohort by the first half of 2026, with a program update anticipated in the latter half of the year.
4D Molecular Therapeutics Reports Positive Interim Data for 4D-710 in Cystic Fibrosis Trial
- Positive Clinical Data: 4D-710 demonstrated good tolerability and achieved physiologically relevant CFTR expression levels in the AEROW trial, indicating potential clinical benefits across multiple lung function and symptom measures, suggesting its promise as a cystic fibrosis treatment.
- Patient Recruitment Progress: As of December 1, 2025, the AEROW trial has enrolled 16 cystic fibrosis patients, with no new safety events reported across different dose cohorts, underscoring the treatment's safety and efficacy.
- Successful Dose Selection: The 2.5E14 vg dose cohort showed clinically meaningful activity across all endpoints, supporting its selection for the next phase and further optimizing the treatment regimen.
- Future Milestones: The company anticipates completing enrollment of the AEROW Phase 2 Dose-Expansion cohort in H1 2026, further validating the efficacy of 4D-710, with plans to share additional updates in H2 2026.
4D Molecular Therapeutics Announces Encouraging Interim Phase 1 Results for 4D-710 in Cystic Fibrosis
Positive Interim Results: 4D Molecular Therapeutics reported encouraging interim results from its Phase 1 AEROW study for 4D-710, a gene therapy for cystic fibrosis, showing significant improvements in lung function over a one-year follow-up.
Durable CFTR Expression: The study demonstrated sustained CFTR transgene expression within the therapeutic range for at least one year, indicating potential long-term benefits for patients.
Future Plans: The company anticipates completing enrollment for the Phase 2 dose-expansion cohort by mid-2026, with an update on the program expected in the latter half of 2026.
Stock Performance: Following the announcement, FDMT shares rose by 5.21%, closing at $11.52.
4D Molecular Therapeutics Grants 13,800 RSUs to New Employees Under Inducement Plan
- Employee Incentive Program: On December 9, 2025, 4D Molecular Therapeutics granted 13,800 Restricted Stock Units (RSUs) to three new non-executive employees, aimed at attracting new talent through the 2025 Employment Inducement Award Plan, thereby enhancing the company's human resource competitiveness.
- Board Approval: The plan was approved by the board in February 2025, complying with Nasdaq Global Market Rule 5635(c)(4), indicating the company's commitment to attracting and retaining key talent, which will further drive its biotechnology innovations.
- Product Development Context: The company's lead product candidate, 4D-150, is currently in Phase 3 clinical trials, designed to provide multi-year sustained anti-VEGF delivery through a single safe intravitreal injection, significantly reducing the treatment burden associated with current methods and improving patient experience.
- Market Potential: With the development of product candidates like 4D-150 and 4D-710, the company is poised to achieve breakthroughs in treating blinding retinal vascular diseases and cystic fibrosis, further solidifying its market position in the biotechnology sector.
